How much funding has GlycoEra raised?

GlycoEra has raised $179.0M in total funding, most recently a Series B round.

Who are GlycoEra's investors?

GlycoEra's investors include Sofinnova Partners, 5AM Ventures, Roche, Novo Holdings A/S, Catalio Capital Management, Bristol Myers Squibb.

Where is GlycoEra headquartered?

GlycoEra is headquartered in Wädenswil, Switzerland.

What industry is GlycoEra in?

GlycoEra operates in Biotech, Healthcare.

GlycoEra

Precision protein degradation to stop autoimmune disease at the source

Wädenswil, Switzerland · $179.0M raised

Biotech

Healthcare

Headquarters: Wädenswil
Employees: 11–50
Business Model: B2B
Website: glycoera.com

Total Funding: $179.0M
Last Round: $130.0M Series BMay 2025
Rounds: 3

About

GlycoEra AG is a Swiss biotechnology company developing precision protein-degrading biologics to treat autoimmune diseases at their root cause. Headquartered on the Tuwag-Areal in Wädenswil, Switzerland, GlycoEra's platform selectively degrades specific circulating autoantibodies rapidly and deeply without broad immune suppression, enabling earlier disease intervention. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies implicated in a range of autoimmune diseases. The company raised a $130 million Series B led by Novo Holdings in 2025 to advance GE8820 through clinical proof-of-concept.

Summary

GlycoEra is a Biotech company based in Wädenswil, Switzerland. It has raised $179.0M in total across 3 rounds, most recently a $130.0M Series B round in May 2025. Investors include Sofinnova Partners, 5AM Ventures and Roche.